The impact of catheter ablation for atrial fibrillation in heart failure.

Journal of Arrhythmia
Konstantinos MoschonasPaul A Scott

Abstract

Atrial fibrillation (AF) commonly co-exists with systolic heart failure (SHF) and its presence is associated with a worse prognosis. Despite this, a rhythm control approach using antiarrhythmic drugs (AADs) to reduce AF burden has demonstrated no prognostic benefit. Catheter ablation (AFA) is more effective than AADs at reducing AF burden. We performed a meta-analysis to evaluate the impact of AFA on outcomes in SHF. Electronic databases were systematically searched. We included only randomized controlled trials that examined the impact of AFA on clinical outcomes in patients with SHF (LVEF <50%). We included studies with any ablation strategy that incorporated pulmonary vein isolation and any control group. Seven studies (n = 858) were included with a mean follow-up of 6-38 months. In comparison to controls, AFA was associated with significant reductions in all-cause mortality (relative risk [RR] 0.52, P = 0.0009) and unplanned or heart failure hospitalization (RR 0.58, P < 0.00001). Compared to controls, AFA was also associated with significant improvements in LVEF (mean difference 6.30%, P < 0.00001), Minnesota Living with Heart Failure Questionnaire score (mean difference 9.58, P = 0.0003), 6-minute walk distance (mean diff...Continue Reading

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Apr 3, 2001·Annals of Internal Medicine·J M BrophyJ L Rouleau
Dec 6, 2002·The New England Journal of Medicine·D G WyseUNKNOWN Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators
Apr 3, 2003·The American Journal of Cardiology·William H Maisel, Lynne Warner Stevenson
Jun 21, 2008·The New England Journal of Medicine·Denis RoyUNKNOWN Atrial Fibrillation and Congestive Heart Failure Investigators
Oct 24, 2008·The New England Journal of Medicine·Mohammed N KhanUNKNOWN PABA-CHF Investigators
Apr 24, 2010·Journal of the American College of Cardiology·Mario TalajicUNKNOWN AF-CHF Investigators
Aug 31, 2013·Circulation Research·Véronique L Roger
Jan 3, 2014·Circulation. Arrhythmia and Electrophysiology·Ross J HunterRichard J Schilling
Sep 7, 2014·Lancet·Dipak KotechaUNKNOWN Beta-Blockers in Heart Failure Collaborative Group
Sep 30, 2014·Circulation. Arrhythmia and Electrophysiology·Matteo AnselminoFiorenzo Gaita
May 7, 2015·The New England Journal of Medicine·Atul VermaUNKNOWN STAR AF II Investigators
Sep 1, 2017·Journal of the American College of Cardiology·Sandeep PrabhuPeter M Kistler
Feb 1, 2018·The New England Journal of Medicine·Nassir F MarroucheUNKNOWN CASTLE-AF Investigators

❮ Previous
Next ❯

Software Mentioned

AF
AFFIRM
Review Manager
STAR
CHF

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.